Clostridium botulinum type A toxin-haemagglutinin complex is a potent neurotoxin derived from the bacterium Clostridium botulinum. It acts as a neuromuscular blocking agent by inhibiting the release of acetylcholine at the neuromuscular junction, leading to temporary, dose-dependent chemical denervation and muscle relaxation. The 500IU strength is a standardized unit of biological activity, crucial for precise dosing in therapeutic applications. In India, it is a critical tool in the management of focal dystonias, spasticity, and cosmetic procedures.
Adult: Dose is HIGHLY INDIVIDUALIZED based on indication, muscle mass, severity, and product used. Examples: Blepharospasm: 1.25-2.5 IU (0.05-0.1 mL volume) per site in 3-5 sites per eye. Cervical Dystonia: 100-200 IU total dose divided among affected muscles. Axillary Hyperhidrosis: 50 IU per axilla (multiple intradermal injections). Chronic Migraine: 155 IU administered as 0.1 mL (5 IU) injections across 31 specific sites in head/neck muscles.
Note: FOR SKILLED PRACTITIONER USE ONLY. Must be reconstituted with sterile, preservative-free 0.9% sodium chloride. Gently swirl, do not shake. Use within 24 hours if refrigerated (4°C). Administered using a fine-gauge needle (e.g., 30-32G) for precise intramuscular or intradermal injection. Electromyographic (EMG) guidance is recommended for deep or small muscles. Avoid intravascular injection.
The toxin binds with high affinity and specificity to receptors on the presynaptic surface of cholinergic nerve terminals. It is internalized via receptor-mediated endocytosis. Inside the cytosol, the light chain cleaves SNAP-25 (Synaptosomal-Associated Protein of 25 kDa), a component of the SNARE complex essential for the fusion of acetylcholine-containing vesicles with the presynaptic membrane. This irreversible inhibition prevents the exocytotic release of acetylcholine, resulting in flaccid paralysis of the target muscle.
Pregnancy: Category C: Animal studies have shown evidence of fetal toxicity and malformations at high doses. There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus.
Driving: May impair ability to drive or operate machinery if muscle weakness affects necessary motor skills (e.g., ptosis impairing vision, neck weakness). Patients should be cautioned until clinical effect is stable.
| Aminoglycosides (e.g., Gentamicin) | May potentiate neuromuscular blocking effect, increasing risk of systemic weakness. | Major |
| Other Neuromuscular Blockers (e.g., succinylcholine) | Additive or synergistic neuromuscular blockade. | Major |
| Anticoagulants/Antiplatelets (e.g., Warfarin, Clopidogrel, NSAIDs) | Increased risk of bleeding and bruising at injection sites. | Moderate |
| Muscle Relaxants (oral, e.g., Baclofen, Tizanidine) | Potential additive effect on muscle weakness. | Moderate |
| Cholinesterase Inhibitors (e.g., Pyridostigmine) | Theoretical antagonism of botulinum toxin effect. | Moderate |